Welcome to the April 10, 2007 edition of Carnival of Biotechnology.
Finance and business development
Bloomberg reports that biotechnology companies can’t find enough scientists to hire, threatening to slow one of the industries bolstering U.S. job growth.
In the pipeline has a cautionary post about Amgen’s attempt to expand the indications of Epogen, resulting in new warning labels on drug packaging and potential charges that it has recklessly endangered patients’ lives.
H.S. Ayoub presents Bruker BioSciences: Earnings Growing, Insiders Buying posted at BioHealth Investor.
Some interesting developments in stem cells.
That concludes this edition.
For more information, see the Carnival of Biotechnology Homepage, or submit a link for the next edition. Interested in hosting a future Carnival of Biotechnology? Let me know.